Literature DB >> 28130034

NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.

Boglarka Mikudina1, Melinda Goodall2, Amanda I Adler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28130034     DOI： 10.1016/S1470-2045(17)30062-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.

Authors:  R Andrew Harkins; Sharvil P Patel; Christopher R Flowers
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 2.  Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.

Authors:  Shigeo Fuji; Arnon Nagler; Mohamad Mohty; Bipin Savani; Roni Shouval
Journal:  Bone Marrow Transplant       Date:  2020-01-13       Impact factor: 5.483

Review 3.  Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

Authors:  Elizabeth M Adkins; Lindsay Nicholson; David Floyd; Mark Ratcliffe; Helene Chevrou-Severac
Journal:  Clinicoecon Outcomes Res       Date:  2017-06-10

4.  Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.

Authors:  James Buchanan; Sarah Wordsworth; Ruth Clifford; Pauline Robbe; Jenny C Taylor; Anna Schuh; Samantha J L Knight
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.